Neptune W B
New England Deaconess Hospital, Harvard Medical School, Boston, MA.
Arch Surg. 1988 May;123(5):583-5. doi: 10.1001/archsurg.1988.01400290065010.
We reviewed 100 operations performed on 95 consecutive patients with stage II (n = 7) and stage III (n = 88) primary lung cancer. The five-year survival of patients with N1 involvement was 58% and with N2 disease was 21%. Of 13 patients with Pancoast or chest wall involvement, 58% survived five years. The entire group had a 34% five-year survival and a median survival of 32 months. Preoperative and/or postoperative radiotherapy, in the presence of nodal disease, appears to improve local control, but an effective chemotherapy program is needed for unrecognized visceral metastases. In the absence of contraindications, surgical excision offers the best likelihood of survival and quality of life.
我们回顾了对95例连续的II期（n = 7）和III期（n = 88）原发性肺癌患者进行的100例手术。N1受累患者的五年生存率为58%，N2疾病患者的五年生存率为21%。在13例有潘科斯特综合征或胸壁受累的患者中，58%存活了五年。整个组的五年生存率为34%，中位生存期为32个月。在存在淋巴结疾病的情况下，术前和/或术后放疗似乎可改善局部控制，但对于未识别的内脏转移需要有效的化疗方案。在没有禁忌证的情况下，手术切除提供了最佳的生存可能性和生活质量。
